Thrombotic Risk Stratification and Intensive Statin Therapy for Secondary Prevention of Coronary Artery Disease ― Insights From the REAL-CAD Study
Background: It is unknown whether beneficial effects of higher-dose statins on cardiovascular events are different according to the thrombotic risk in patients with chronic coronary syndrome (CCS).Methods and Results: The Randomized Evaluation of Aggressive or Moderate Lipid-Lowering Therapy with Pi...
Gespeichert in:
| Veröffentlicht in: | Circulation Journal 2022/08/25, Vol.86(9), pp.1416-1427 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1427 |
|---|---|
| container_issue | 9 |
| container_start_page | 1416 |
| container_title | Circulation Journal |
| container_volume | 86 |
| creator | Natsuaki, Masahiro Morimoto, Takeshi Iimuro, Satoshi Fujita, Retsu Iwata, Hiroshi Miyauchi, Katsumi Inoue, Teruo Nakagawa, Yoshihisa Nishihata, Yosuke Daida, Hiroyuki Ozaki, Yukio Suwa, Satoru Sakuma, Ichiro Furukawa, Yutaka Shiomi, Hiroki Watanabe, Hirotoshi Yamaji, Kyohei Saito, Naritatsu Matsuzaki, Masunori Nagai, Ryozo Kimura, Takeshi on behalf of the REAL-CAD Investigators |
| description | Background: It is unknown whether beneficial effects of higher-dose statins on cardiovascular events are different according to the thrombotic risk in patients with chronic coronary syndrome (CCS).Methods and Results: The Randomized Evaluation of Aggressive or Moderate Lipid-Lowering Therapy with Pitavastatin in Coronary Artery Disease (REAL-CAD) study is a randomized trial comparing 4 mg and 1 mg pitavastatin in patients with CCS. This study categorized 12,413 patients into 3 strata according to the CREDO-Kyoto thrombotic risk score: low-risk (N=9,434; 4 mg: N=4,742, and 1 mg: N=4,692), intermediate-risk (N=2,415; 4 mg: N=1,188, and 1 mg: N=1,227); and high-risk (N=564; 4 mg: N=269, and 1 mg: N=295). The primary endpoint was a composite of cardiovascular death, non-fatal myocardial infarction, non-fatal ischemic stroke, or unstable angina. Cumulative 4-year incidence of the primary endpoint was significantly higher in the high-risk stratum than in the intermediate- and low-risk strata (11.0%, 6.3%, and 4.5%, P |
| doi_str_mv | 10.1253/circj.CJ-22-0315 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2699956241</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2699956241</sourcerecordid><originalsourceid>FETCH-LOGICAL-c578t-e2c8b75493846ebc022dc084df030022b443498a7fbe58e152f7f31859ec3dce3</originalsourceid><addsrcrecordid>eNpFkU1vEzEQhleIipbCnRPykcsWrz927WO0baBVJVAbzpbXO9t1SOxgO5Vyy5-AHwh_BOej7WXGGj_zjmbeovhQ4YuKcPrZ2GDmF-1NSUiJacVfFWcVZU3JBMGv9--6lILR0-JtjHOMicRcvilOKZcZa8RZ8Wc2Br_sfLIG3dn4E92noJMdrMnRO6Rdj65dAhftI-TPXHVoNkLQqw0afED3YLzrddig7wEewe27_IBaH7zblSchQU6XNoKO8G-7_bv9nSWjfRhTRNM8HaUR0N3V5LZsJ5d5xrrfvCtOBr2I8P6Yz4sf06tZ-7W8_fblus2k4Y1IJRAjuoYzSQWroTOYkN5gwfoB07wt6RijTArdDB1wARUnQzPQSnAJhvYG6Hnx6aC7Cv7XGmJSSxsNLBbagV9HRWopJa8JqzKKD6gJPsYAg1oFu8wbqgqrnRtq74ZqbxQhaudGbvl4VF93S-ifG57On4HpAZjHpB_gGdAh-7GAo6KoldyFF-UXYNRBgaP_AYE2o6Y</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2699956241</pqid></control><display><type>article</type><title>Thrombotic Risk Stratification and Intensive Statin Therapy for Secondary Prevention of Coronary Artery Disease ― Insights From the REAL-CAD Study</title><source>J-STAGE Free</source><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>Natsuaki, Masahiro ; Morimoto, Takeshi ; Iimuro, Satoshi ; Fujita, Retsu ; Iwata, Hiroshi ; Miyauchi, Katsumi ; Inoue, Teruo ; Nakagawa, Yoshihisa ; Nishihata, Yosuke ; Daida, Hiroyuki ; Ozaki, Yukio ; Suwa, Satoru ; Sakuma, Ichiro ; Furukawa, Yutaka ; Shiomi, Hiroki ; Watanabe, Hirotoshi ; Yamaji, Kyohei ; Saito, Naritatsu ; Matsuzaki, Masunori ; Nagai, Ryozo ; Kimura, Takeshi ; on behalf of the REAL-CAD Investigators</creator><creatorcontrib>Natsuaki, Masahiro ; Morimoto, Takeshi ; Iimuro, Satoshi ; Fujita, Retsu ; Iwata, Hiroshi ; Miyauchi, Katsumi ; Inoue, Teruo ; Nakagawa, Yoshihisa ; Nishihata, Yosuke ; Daida, Hiroyuki ; Ozaki, Yukio ; Suwa, Satoru ; Sakuma, Ichiro ; Furukawa, Yutaka ; Shiomi, Hiroki ; Watanabe, Hirotoshi ; Yamaji, Kyohei ; Saito, Naritatsu ; Matsuzaki, Masunori ; Nagai, Ryozo ; Kimura, Takeshi ; on behalf of the REAL-CAD Investigators ; REAL-CAD Investigators ; on behalf of the REAL-CAD Investigators</creatorcontrib><description>Background: It is unknown whether beneficial effects of higher-dose statins on cardiovascular events are different according to the thrombotic risk in patients with chronic coronary syndrome (CCS).Methods and Results: The Randomized Evaluation of Aggressive or Moderate Lipid-Lowering Therapy with Pitavastatin in Coronary Artery Disease (REAL-CAD) study is a randomized trial comparing 4 mg and 1 mg pitavastatin in patients with CCS. This study categorized 12,413 patients into 3 strata according to the CREDO-Kyoto thrombotic risk score: low-risk (N=9,434; 4 mg: N=4,742, and 1 mg: N=4,692), intermediate-risk (N=2,415; 4 mg: N=1,188, and 1 mg: N=1,227); and high-risk (N=564; 4 mg: N=269, and 1 mg: N=295). The primary endpoint was a composite of cardiovascular death, non-fatal myocardial infarction, non-fatal ischemic stroke, or unstable angina. Cumulative 4-year incidence of the primary endpoint was significantly higher in the high-risk stratum than in the intermediate- and low-risk strata (11.0%, 6.3%, and 4.5%, P<0.0001). In the low-risk stratum, the cumulative 4-year incidence of the primary endpoint was significantly lower in the 4 mg than in the 1 mg group (4.0% and 4.9%, P=0.02), whereas in the intermediate- and high-risk strata, it was numerically lower in the 4 mg than in the 1 mg group. There was no significant treatment-by-subgroup interaction for the primary endpoint (P-interaction=0.77).Conclusions: High-dose pitavastatin therapy compared with low-dose pitavastatin therapy was associated with a trend toward lowering the risk for cardiovascular events irrespective of the thrombotic risk in patients with CCS.</description><identifier>ISSN: 1346-9843</identifier><identifier>ISSN: 1347-4820</identifier><identifier>EISSN: 1347-4820</identifier><identifier>DOI: 10.1253/circj.CJ-22-0315</identifier><identifier>PMID: 35934778</identifier><language>eng</language><publisher>Japan: The Japanese Circulation Society</publisher><subject>Angina, Unstable - prevention & control ; Coronary Artery Disease - drug therapy ; Humans ; Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects ; Percutaneous coronary intervention ; Risk Assessment ; Secondary Prevention ; Statin therapy ; Thrombotic risk ; Treatment Outcome</subject><ispartof>Circulation Journal, 2022/08/25, Vol.86(9), pp.1416-1427</ispartof><rights>2022, THE JAPANESE CIRCULATION SOCIETY</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c578t-e2c8b75493846ebc022dc084df030022b443498a7fbe58e152f7f31859ec3dce3</citedby><cites>FETCH-LOGICAL-c578t-e2c8b75493846ebc022dc084df030022b443498a7fbe58e152f7f31859ec3dce3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,1877,27903,27904</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35934778$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Natsuaki, Masahiro</creatorcontrib><creatorcontrib>Morimoto, Takeshi</creatorcontrib><creatorcontrib>Iimuro, Satoshi</creatorcontrib><creatorcontrib>Fujita, Retsu</creatorcontrib><creatorcontrib>Iwata, Hiroshi</creatorcontrib><creatorcontrib>Miyauchi, Katsumi</creatorcontrib><creatorcontrib>Inoue, Teruo</creatorcontrib><creatorcontrib>Nakagawa, Yoshihisa</creatorcontrib><creatorcontrib>Nishihata, Yosuke</creatorcontrib><creatorcontrib>Daida, Hiroyuki</creatorcontrib><creatorcontrib>Ozaki, Yukio</creatorcontrib><creatorcontrib>Suwa, Satoru</creatorcontrib><creatorcontrib>Sakuma, Ichiro</creatorcontrib><creatorcontrib>Furukawa, Yutaka</creatorcontrib><creatorcontrib>Shiomi, Hiroki</creatorcontrib><creatorcontrib>Watanabe, Hirotoshi</creatorcontrib><creatorcontrib>Yamaji, Kyohei</creatorcontrib><creatorcontrib>Saito, Naritatsu</creatorcontrib><creatorcontrib>Matsuzaki, Masunori</creatorcontrib><creatorcontrib>Nagai, Ryozo</creatorcontrib><creatorcontrib>Kimura, Takeshi</creatorcontrib><creatorcontrib>on behalf of the REAL-CAD Investigators</creatorcontrib><creatorcontrib>REAL-CAD Investigators</creatorcontrib><creatorcontrib>on behalf of the REAL-CAD Investigators</creatorcontrib><title>Thrombotic Risk Stratification and Intensive Statin Therapy for Secondary Prevention of Coronary Artery Disease ― Insights From the REAL-CAD Study</title><title>Circulation Journal</title><addtitle>Circ J</addtitle><description>Background: It is unknown whether beneficial effects of higher-dose statins on cardiovascular events are different according to the thrombotic risk in patients with chronic coronary syndrome (CCS).Methods and Results: The Randomized Evaluation of Aggressive or Moderate Lipid-Lowering Therapy with Pitavastatin in Coronary Artery Disease (REAL-CAD) study is a randomized trial comparing 4 mg and 1 mg pitavastatin in patients with CCS. This study categorized 12,413 patients into 3 strata according to the CREDO-Kyoto thrombotic risk score: low-risk (N=9,434; 4 mg: N=4,742, and 1 mg: N=4,692), intermediate-risk (N=2,415; 4 mg: N=1,188, and 1 mg: N=1,227); and high-risk (N=564; 4 mg: N=269, and 1 mg: N=295). The primary endpoint was a composite of cardiovascular death, non-fatal myocardial infarction, non-fatal ischemic stroke, or unstable angina. Cumulative 4-year incidence of the primary endpoint was significantly higher in the high-risk stratum than in the intermediate- and low-risk strata (11.0%, 6.3%, and 4.5%, P<0.0001). In the low-risk stratum, the cumulative 4-year incidence of the primary endpoint was significantly lower in the 4 mg than in the 1 mg group (4.0% and 4.9%, P=0.02), whereas in the intermediate- and high-risk strata, it was numerically lower in the 4 mg than in the 1 mg group. There was no significant treatment-by-subgroup interaction for the primary endpoint (P-interaction=0.77).Conclusions: High-dose pitavastatin therapy compared with low-dose pitavastatin therapy was associated with a trend toward lowering the risk for cardiovascular events irrespective of the thrombotic risk in patients with CCS.</description><subject>Angina, Unstable - prevention & control</subject><subject>Coronary Artery Disease - drug therapy</subject><subject>Humans</subject><subject>Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects</subject><subject>Percutaneous coronary intervention</subject><subject>Risk Assessment</subject><subject>Secondary Prevention</subject><subject>Statin therapy</subject><subject>Thrombotic risk</subject><subject>Treatment Outcome</subject><issn>1346-9843</issn><issn>1347-4820</issn><issn>1347-4820</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpFkU1vEzEQhleIipbCnRPykcsWrz927WO0baBVJVAbzpbXO9t1SOxgO5Vyy5-AHwh_BOej7WXGGj_zjmbeovhQ4YuKcPrZ2GDmF-1NSUiJacVfFWcVZU3JBMGv9--6lILR0-JtjHOMicRcvilOKZcZa8RZ8Wc2Br_sfLIG3dn4E92noJMdrMnRO6Rdj65dAhftI-TPXHVoNkLQqw0afED3YLzrddig7wEewe27_IBaH7zblSchQU6XNoKO8G-7_bv9nSWjfRhTRNM8HaUR0N3V5LZsJ5d5xrrfvCtOBr2I8P6Yz4sf06tZ-7W8_fblus2k4Y1IJRAjuoYzSQWroTOYkN5gwfoB07wt6RijTArdDB1wARUnQzPQSnAJhvYG6Hnx6aC7Cv7XGmJSSxsNLBbagV9HRWopJa8JqzKKD6gJPsYAg1oFu8wbqgqrnRtq74ZqbxQhaudGbvl4VF93S-ifG57On4HpAZjHpB_gGdAh-7GAo6KoldyFF-UXYNRBgaP_AYE2o6Y</recordid><startdate>20220825</startdate><enddate>20220825</enddate><creator>Natsuaki, Masahiro</creator><creator>Morimoto, Takeshi</creator><creator>Iimuro, Satoshi</creator><creator>Fujita, Retsu</creator><creator>Iwata, Hiroshi</creator><creator>Miyauchi, Katsumi</creator><creator>Inoue, Teruo</creator><creator>Nakagawa, Yoshihisa</creator><creator>Nishihata, Yosuke</creator><creator>Daida, Hiroyuki</creator><creator>Ozaki, Yukio</creator><creator>Suwa, Satoru</creator><creator>Sakuma, Ichiro</creator><creator>Furukawa, Yutaka</creator><creator>Shiomi, Hiroki</creator><creator>Watanabe, Hirotoshi</creator><creator>Yamaji, Kyohei</creator><creator>Saito, Naritatsu</creator><creator>Matsuzaki, Masunori</creator><creator>Nagai, Ryozo</creator><creator>Kimura, Takeshi</creator><creator>on behalf of the REAL-CAD Investigators</creator><general>The Japanese Circulation Society</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20220825</creationdate><title>Thrombotic Risk Stratification and Intensive Statin Therapy for Secondary Prevention of Coronary Artery Disease ― Insights From the REAL-CAD Study</title><author>Natsuaki, Masahiro ; Morimoto, Takeshi ; Iimuro, Satoshi ; Fujita, Retsu ; Iwata, Hiroshi ; Miyauchi, Katsumi ; Inoue, Teruo ; Nakagawa, Yoshihisa ; Nishihata, Yosuke ; Daida, Hiroyuki ; Ozaki, Yukio ; Suwa, Satoru ; Sakuma, Ichiro ; Furukawa, Yutaka ; Shiomi, Hiroki ; Watanabe, Hirotoshi ; Yamaji, Kyohei ; Saito, Naritatsu ; Matsuzaki, Masunori ; Nagai, Ryozo ; Kimura, Takeshi ; on behalf of the REAL-CAD Investigators</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c578t-e2c8b75493846ebc022dc084df030022b443498a7fbe58e152f7f31859ec3dce3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Angina, Unstable - prevention & control</topic><topic>Coronary Artery Disease - drug therapy</topic><topic>Humans</topic><topic>Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects</topic><topic>Percutaneous coronary intervention</topic><topic>Risk Assessment</topic><topic>Secondary Prevention</topic><topic>Statin therapy</topic><topic>Thrombotic risk</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Natsuaki, Masahiro</creatorcontrib><creatorcontrib>Morimoto, Takeshi</creatorcontrib><creatorcontrib>Iimuro, Satoshi</creatorcontrib><creatorcontrib>Fujita, Retsu</creatorcontrib><creatorcontrib>Iwata, Hiroshi</creatorcontrib><creatorcontrib>Miyauchi, Katsumi</creatorcontrib><creatorcontrib>Inoue, Teruo</creatorcontrib><creatorcontrib>Nakagawa, Yoshihisa</creatorcontrib><creatorcontrib>Nishihata, Yosuke</creatorcontrib><creatorcontrib>Daida, Hiroyuki</creatorcontrib><creatorcontrib>Ozaki, Yukio</creatorcontrib><creatorcontrib>Suwa, Satoru</creatorcontrib><creatorcontrib>Sakuma, Ichiro</creatorcontrib><creatorcontrib>Furukawa, Yutaka</creatorcontrib><creatorcontrib>Shiomi, Hiroki</creatorcontrib><creatorcontrib>Watanabe, Hirotoshi</creatorcontrib><creatorcontrib>Yamaji, Kyohei</creatorcontrib><creatorcontrib>Saito, Naritatsu</creatorcontrib><creatorcontrib>Matsuzaki, Masunori</creatorcontrib><creatorcontrib>Nagai, Ryozo</creatorcontrib><creatorcontrib>Kimura, Takeshi</creatorcontrib><creatorcontrib>on behalf of the REAL-CAD Investigators</creatorcontrib><creatorcontrib>REAL-CAD Investigators</creatorcontrib><creatorcontrib>on behalf of the REAL-CAD Investigators</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Circulation Journal</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Natsuaki, Masahiro</au><au>Morimoto, Takeshi</au><au>Iimuro, Satoshi</au><au>Fujita, Retsu</au><au>Iwata, Hiroshi</au><au>Miyauchi, Katsumi</au><au>Inoue, Teruo</au><au>Nakagawa, Yoshihisa</au><au>Nishihata, Yosuke</au><au>Daida, Hiroyuki</au><au>Ozaki, Yukio</au><au>Suwa, Satoru</au><au>Sakuma, Ichiro</au><au>Furukawa, Yutaka</au><au>Shiomi, Hiroki</au><au>Watanabe, Hirotoshi</au><au>Yamaji, Kyohei</au><au>Saito, Naritatsu</au><au>Matsuzaki, Masunori</au><au>Nagai, Ryozo</au><au>Kimura, Takeshi</au><au>on behalf of the REAL-CAD Investigators</au><aucorp>REAL-CAD Investigators</aucorp><aucorp>on behalf of the REAL-CAD Investigators</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Thrombotic Risk Stratification and Intensive Statin Therapy for Secondary Prevention of Coronary Artery Disease ― Insights From the REAL-CAD Study</atitle><jtitle>Circulation Journal</jtitle><addtitle>Circ J</addtitle><date>2022-08-25</date><risdate>2022</risdate><volume>86</volume><issue>9</issue><spage>1416</spage><epage>1427</epage><pages>1416-1427</pages><artnum>CJ-22-0315</artnum><issn>1346-9843</issn><issn>1347-4820</issn><eissn>1347-4820</eissn><abstract>Background: It is unknown whether beneficial effects of higher-dose statins on cardiovascular events are different according to the thrombotic risk in patients with chronic coronary syndrome (CCS).Methods and Results: The Randomized Evaluation of Aggressive or Moderate Lipid-Lowering Therapy with Pitavastatin in Coronary Artery Disease (REAL-CAD) study is a randomized trial comparing 4 mg and 1 mg pitavastatin in patients with CCS. This study categorized 12,413 patients into 3 strata according to the CREDO-Kyoto thrombotic risk score: low-risk (N=9,434; 4 mg: N=4,742, and 1 mg: N=4,692), intermediate-risk (N=2,415; 4 mg: N=1,188, and 1 mg: N=1,227); and high-risk (N=564; 4 mg: N=269, and 1 mg: N=295). The primary endpoint was a composite of cardiovascular death, non-fatal myocardial infarction, non-fatal ischemic stroke, or unstable angina. Cumulative 4-year incidence of the primary endpoint was significantly higher in the high-risk stratum than in the intermediate- and low-risk strata (11.0%, 6.3%, and 4.5%, P<0.0001). In the low-risk stratum, the cumulative 4-year incidence of the primary endpoint was significantly lower in the 4 mg than in the 1 mg group (4.0% and 4.9%, P=0.02), whereas in the intermediate- and high-risk strata, it was numerically lower in the 4 mg than in the 1 mg group. There was no significant treatment-by-subgroup interaction for the primary endpoint (P-interaction=0.77).Conclusions: High-dose pitavastatin therapy compared with low-dose pitavastatin therapy was associated with a trend toward lowering the risk for cardiovascular events irrespective of the thrombotic risk in patients with CCS.</abstract><cop>Japan</cop><pub>The Japanese Circulation Society</pub><pmid>35934778</pmid><doi>10.1253/circj.CJ-22-0315</doi><tpages>12</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1346-9843 |
| ispartof | Circulation Journal, 2022/08/25, Vol.86(9), pp.1416-1427 |
| issn | 1346-9843 1347-4820 1347-4820 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2699956241 |
| source | J-STAGE Free; MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals |
| subjects | Angina, Unstable - prevention & control Coronary Artery Disease - drug therapy Humans Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects Percutaneous coronary intervention Risk Assessment Secondary Prevention Statin therapy Thrombotic risk Treatment Outcome |
| title | Thrombotic Risk Stratification and Intensive Statin Therapy for Secondary Prevention of Coronary Artery Disease ― Insights From the REAL-CAD Study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-28T04%3A52%3A17IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Thrombotic%20Risk%20Stratification%20and%20Intensive%20Statin%20Therapy%20for%20Secondary%20Prevention%20of%20Coronary%20Artery%20Disease%E3%80%80%E2%80%95%20Insights%20From%20the%20REAL-CAD%20Study&rft.jtitle=Circulation%20Journal&rft.au=Natsuaki,%20Masahiro&rft.aucorp=REAL-CAD%20Investigators&rft.date=2022-08-25&rft.volume=86&rft.issue=9&rft.spage=1416&rft.epage=1427&rft.pages=1416-1427&rft.artnum=CJ-22-0315&rft.issn=1346-9843&rft.eissn=1347-4820&rft_id=info:doi/10.1253/circj.CJ-22-0315&rft_dat=%3Cproquest_cross%3E2699956241%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2699956241&rft_id=info:pmid/35934778&rfr_iscdi=true |